{
    "nct_id": "NCT06630234",
    "official_title": "A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)",
    "inclusion_criteria": "Module A Part 1 (Escalation):\n\n* Any participant with histologically or cytologically confirmed advanced/unresectable or metastatic GIST with documented KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced/metastatic setting\n* Have at least 1 measurable lesion as defined by mRECIST, v1.1\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1\n* Adequate organ function, bone marrow function, and electrolytes\n* All participants agree to comply with the contraception requirements\n* Have a life expectancy of more than 3 months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received systemic anticancer therapy or radiotherapy within 14 days prior to first dose of study drug\n* Prior or concurrent malignancy that requires treatment or is expected to require treatment for active cancer\n* Has known active central nervous system (CNS) metastases or an active primary CNS cancer\n* History or presence of clinically relevant cardiovascular abnormalities\n* Major surgery within 28 days of the first dose of study drug\n* Had systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug\n* Had venous thrombotic events (e.g., deep vein thrombosis) or venous thrombotic embolic events (e.g., pulmonary embolism) within 1 month prior to the first dose of study drug\n* Known allergy or hypersensitivity to any component of the study drug\n* Malabsorption syndrome or other illness that could affect oral absorption\n* Any other clinically significant comorbidities",
    "miscellaneous_criteria": ""
}